Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism

Influence of Recipient Cytochrome P450 3A5 Polymorphism on the Metabolism of Prolonged Release Tacrolimus Administered de Novo After Renal Transplantation

To optimize the Advagraf (tacrolimus once a day) initial daily dose used in de novo after kidney transplantation in combination with MMF (or MPA) and corticosteroids (CS) regarding of the genetic Cyp 450 3A5 polymorphism of the recipient.

The study of the tacrolimus through level (ng/ml) determines if the therapeutic level is reached.

Inclusion Criteria:

• First or second Kidney Transplantation from deceased or living donor

Exclusion Criteria:

• Donor age < 5 years.
• Patients who require plasma exchange because of high immunological risk